The Philippine Health Insurance Corporation (PhilHealth) clarifies that the suspension of the Interim Reimbursement Mechanism (IRM) will not affect the availment of COVID-19 benefits or any of its regular benefits by its members. The suspension of the IRM is to give way for its review in light of the recent Senate and Congressional hearings.
Patients who need hospitalization, SARS-CoV-2 testing, and community isolation are assured of PhilHealth coverage through its Covid-19 benefit packages.
PhilHealth reaffirms the legality and necessity of the IRM in the overall COVID-19 response of the country. The releases follow the strict rules as stated in its Circular No. 2020-0007 which specifies the process by which IRM funding can be obtained by the healthcare facilities. PhilHealth strongly dismisses allegations of 'favoritism' in the disbursement of IRM funds.
PhilHealth acknowledges the continuing clamor of hospitals for the reinstatement of the IRM. We vow to continue working with the legislators and all the investigating bodies in order to address all of their concerns.
ARNEL F. DE JESUS
Executive Vice-President and Chief Operating Officer